Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
June 14 2021 - 04:00PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM
12b-25
NOTIFICATION OF LATE FILING
SEC FILE NUMBER:
|
000-55994
|
(Check One):
|
☐
|
Form 10-K
|
☐
|
Form 20-F
|
☐
|
Form 11-K
|
☒
|
Form 10-Q
|
☐
|
Form N-SAR
|
☐
|
Form N-CSR
|
|
For Period Ended: April 30,
2021
|
|
|
|
|
☐
|
Transition Report on Form 10-K
|
|
☐
|
Transition Report on Form 20-F
|
|
☐
|
Transition Report on Form 11-K
|
|
☐
|
Transition Report on Form 10-Q
|
|
☐
|
Transition Report on Form N-SAR
|
For the Transition
Period Ended:
Nothing in this
form shall be construed to imply that the Commission
has
verified any
information contained herein.
|
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
PART I -- REGISTRANT INFORMATION
THC
THERAPEUTICS, INC.
|
Full Name of Registrant
|
|
|
Former Name if
Applicable
|
|
11700 W Charleston Blvd. #73
|
Address of Principal Executive Office (Street and
Number) |
|
Las Vegas,
Nevada 89135
|
City, State and Zip Code
|
PART II -- RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if
appropriate)
|
(a)
|
The reasons described in reasonable detail in
Part III of this form could not be eliminated without unreasonable
effort or expense;
|
|
|
|
☒
|
(b)
|
The subject annual report, semi-annual
report, transition report on Form 10-K, Form 20-F, Form 11-K or
Form N-SAR, or portion thereof will be filed on or before the 15th
calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, or portion
thereof will be filed on or before the fifth calendar day following
the prescribed due date; and
|
|
|
|
|
(c)
|
The accountant's statement or other exhibit
required by Rule 12b-25(c) has been attached if applicable.
|
PART III -- NARRATIVE
State below in reasonable detail the reasons why Forms 10-Q, 10-K,
20-F, 11-K, 10-Q, N-SAR, or the transition report portion thereof,
could not be filed within the prescribed time period.
The accountants could not complete the required financial
statements, the auditors could not complete their review of the
financial statements and periodic report, and management could not
complete the Management’s Discussion and Analysis of such financial
statements prior to the filing deadline.
PART IV-- OTHER INFORMATION
(1)
|
Name and telephone
number of person to contact in regard to this notification
|
Brandon
Romanek
|
|
833
|
|
420-8428
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2)
|
Have all other periodic
reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If
answer is no, identify report(s). Yes ☒ No
☐
|
(3)
|
Is it anticipated that
any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by
the earnings statements to be included in the subject report or
portion thereof? Yes ☐ No ☒
|
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be
made.
THC
Therapeutics, Inc.
(Name of
Registrant as Specified in Charter)
|
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: June 14, 2021
|
By:
|
/s/ Brandon Romanek
|
|
|
|
Brandon Romanek, President
|
|
THC Therapeutics (PK) (USOTC:THCT)
Historical Stock Chart
From Apr 2022 to May 2022
THC Therapeutics (PK) (USOTC:THCT)
Historical Stock Chart
From May 2021 to May 2022